Haven't lost any weight on Mounjaro? What the evidence actually says

The biggest misconception: a still scale means the medicine isn't working

Most people who report not having lost weight on Mounjaro check the scales after two or three weeks at 2.5mg and conclude the treatment has failed them. That's understandable, but it's almost certainly the wrong conclusion. The starting dose exists to let your body adjust gradually, nausea is a real barrier to sticking with treatment, and 2.5mg keeps that risk low. Its job is preparation, not transformation.

The clinical trial evidence that supports tirzepatide's UK licence (published in the New England Journal of Medicine (SURMOUNT-1)) followed participants for 72 weeks, with doses escalating from 2.5mg up to 15mg over the course of the programme. Average weight reduction at the highest doses reached around 20–21% of body weight. That outcome didn't arrive in week three. It built over months as the dose climbed and as the body responded cumulatively. Comparing your week-four result to a trial's 72-week headline is a mismatch that will make Mounjaro look like it isn't working even when it is.

Scale weight also captures water, muscle, food in transit and hormonal shifts, all of which fluctuate day to day. Someone losing fat but gaining muscle through exercise, or retaining fluid around a menstrual cycle, may see no movement for a fortnight. Worth keeping a note of waist measurements alongside weight.

Three real reasons people don't lose weight, or lose less than expected

There are situations where a lack of progress reflects something specific rather than just patience running low. The NHS medicines page for tirzepatide is clear that tirzepatide works alongside a reduced-calorie diet and increased physical activity, not instead of them. If appetite suppression is modest at a lower dose, calorie intake can remain higher than people realise, particularly with calorie-dense foods that take up little physical space in the stomach.

Sleep is underrated here. Persistent poor sleep raises cortisol and ghrelin, the hormones that drive hunger, and suppresses leptin. GLP-1 medicines act on appetite signalling, but they're swimming against a strong current when those stress hormones are chronically elevated. Similarly, undiagnosed or undertreated hypothyroidism slows metabolism considerably; if weight has been very stubborn across several years, it's worth asking a GP to check thyroid function if that hasn't been done recently.

A third factor is dose. Many people find limited progress at 2.5mg or 5mg that improves meaningfully once they reach a therapeutic maintenance dose under prescriber supervision. Staying on the starter dose indefinitely (which sometimes happens when people self-manage without clinical review) means never giving the medicine a fair trial. Our tirzepatide overview covers how the escalation schedule is structured and why prescriber-led titration matters.

When to have a proper conversation with your prescriber

There's a formal review point built into UK clinical guidance. NICE's appraisal of tirzepatide (TA1026) recommends that if fewer than 5% of body weight has been lost after six months at the highest tolerated dose, continuing treatment should be reviewed. That's a useful marker, it means that a lack of progress at 2.5mg in month one isn't a signal to stop, but sustained poor response at an adequate dose after six months is worth investigating properly.

If you're some way into treatment and genuinely not seeing progress, a prescriber can look at several things: whether your current dose is the highest clinically appropriate one, whether something else is affecting your response, and whether any aspect of your eating pattern or activity level needs adjustment alongside the medicine. That's a clinical conversation, not a Google search. People sometimes feel embarrassed to raise the question, it comes up regularly with our prescribers, and there's usually a practical reason and a practical next step.

For context on how weight-loss treatment works more broadly, the treatment options overview sets out what realistic expectations look like and how Mounjaro fits within the wider picture. Some people also find it reassuring to read whether others have experienced the same, they have, and the reasons are usually identifiable.

Side effects that can look like a lack of progress

A few things that accompany early treatment can temporarily obscure weight changes. Nausea that reduces appetite but also limits what you can eat can produce a week or two of apparent plateau before the medicine's appetite-suppressing effect settles into a more consistent pattern. Constipation (common in the first weeks) adds to scale weight in a way that has nothing to do with fat. Hair shedding, which some people notice a few months in, is linked to the physical stress of rapid weight change rather than to the medicine directly; more on that on our hair shedding page.

None of this is a reason to stop treatment without speaking to a prescriber first. Stopping abruptly doesn't give the medicine a fair chance, and it means losing whatever progress has accumulated. If you're partway through treatment and haven't lost any weight on Mounjaro yet, that's exactly the kind of situation a prescriber review is designed to help with, rather than a reason to stop. For a detailed look at what different patterns of non-response might mean, if you feel you've lost no weight on Mounjaro despite sticking with it, the why-haven't-I-lost-weight explainer goes deeper into the underlying mechanisms. If you're weighing up whether to continue or switch, our prescribers can help you think through the options, you can start a free consultation and get a same-day clinical review by a GPhC-registered prescriber, not a chatbot.